ArticleHepatobiliary surgery and nutrition2026
Enhanced long-term outcomes with laparoscopic bariatric surgery in patients with severe obesity and metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bariatric surgery is a potential treatment for weight loss in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and severe obesity. However, the impact of bariatric surgery types on long-term outcomes and healthcare utilization in this population has not been well characterized. We aimed to compare long-term outcomes and healthcare utilization between laparoscopic and open bariatric surgery in patients with MASLD and severe obesity. Methods: We conducted a retrospective cohort of adult patients with MASLD and severe obesity [body mass index (BMI) ≥35 kg/m Results: The study included 46,476 patients with MASLD and severe obesity. A 1:1 PSM yielded 5,629 matched pairs of patients with laparoscopic or open bariatric surgery for analysis. Among different bariatric surgery types, Roux-en-Y gastric bypass (RYGB) was the dominant procedure up to 2012, whereas over 50% of bariatric procedures were sleeve gastrectomy (SG) after 2015. In multivariable analysis, laparoscopic surgery was associated with a 47% reduced risk of any liver-related outcomes [adjusted hazard ratio (aHR) =0.53; 95% confidence interval (CI): 0.42-0.67; P<0.001], 67% reduced risk of CVD (aHR =0.33; 95% CI: 0.28-0.40; P<0.001), 56% reduced risk of CKD (aHR =0.44; 95% CI: 0.36-0.54; P<0.001), and 42% reduced risk of obesity-related cancers (aHR =0.58; 95% CI: 0.42-0.80; P<0.001), compared to those with open surgery. Patients with laparoscopic surgery had fewer hospitalization (0.04 Conclusions: Laparoscopic surgery is a promising potential treatment for patients with MASLD and severe obesity with more favorable long-term outcomes and healthcare utilization and costs than open surgery. Randomized clinical trials and additional cost-effectiveness analysis are needed to corroborate the findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.